Lipid Testing After Myocardial Infarction at the Montreal Heart Institute

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMontreal Heart Institute

About this trial

Because treatment decisions are usually based on a single measurement of the lipid panel at the time of an admission for an MI, the overarching objective of this project is to evaluate whether the measurement of LDL, non-HDL, and apoB values are reliable through all the duration of the hospitalization.

It will be a single-center, prospective, observational study will be conducted, including consecutive patients hospitalized for myocardial infarction at the Montreal Heart Institute.

Every patient at the Cardiac Care Unit will undergo non-fasting lipid panel testing at day 0 of their admission for Myocardial Infarction during the study period. Patients who consent to participate will have a 2nd non-fasting lipid panel drawn at day 2 of their admission.

Thereafter, the levels of the different lipid values from the panel will be compared between day 0, day 2, and 4-6 weeks after discharge.

Eligibility criteria

Qualifiers

Adult patients ≥18 years old

Hospitalized at the Cardiac Care Unit for Myocardial Infarction (either NSTEMI or STEMI)

Lipid panel performed on day 0 of admission

Willing to provide informed consent

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Lipid panel

Treatment groups

No treatment groups listed

Sponsors and collaborators

Montreal Heart Institute

Lead sponsor

Novartis Pharmaceuticals

Collaborator